

Literaturverzeichnis

- Abbott WG, Foley JE et al. Comparison of body composition, adipocyte size and glucose and insulin concentrations in Pima Indian and Caucasian children. *Metabolis.* 1987; **36**: 576-579.
- ADA: Follow-up Report on the Diagnosis of Diabetes Mellitus. *Diabetes Care* 2003; **26** (11): 3160-3167.
- Altshuler D, Hirschhorn JN, Klannemark M et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. *Nat. Gen.* 2000; **26**: 76-80.
- Auboeuf D, Rieusset J, Fajas L et al. Tissue distribution and quantification of the expression of mRNAs of Peroxisome Proliferator-Activated Receptors and Liver X Receptor- α in humans. No Alteration in Adipose Tissue of Obese and NIDDM Patients. *Diabetes* 1997; **46**: 1319-1327.
- Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). *Diabetic Med.* 1999; **16** (5): 442-443.
- Beamer BA, Yen CJ, Andersen RE et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma 2 gene with obesity in two Caucasian populations. *Diabetes* 1998; **47**: 1806-1808.
- Bell DS. Inflammation, Insulin resistance, Infection, Diabetes, and Atherosclerosis. *Endocr. Pract.* 2000; **6** (3): 272-276.
- Bergmann RN. Quantitative estimation of insulin sensitivity. *Am. J. Physiol.* 1979; **236**: E 667-E 677.
- Bernal D, Almind K, Yenush L et al. Insulin receptor substrate-2 amino acid polymorphisms are not associated with random type 2 diabetes among Caucasians. *Diabetes* 1998; **47**: 976-979.
- Betteridge D. LDL heterogeneity: implications for atherogenicity in insulin resistance and NIDDM. *Diabetologia* 1997; **40** (Suppl. 2): 149-151.
- Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. *Br. J. Pharmacol.* 2000; **129** (5): 823-834.
- Bloomgarden ZT. Insulin Resistance: Current Concepts. *Clin. Ther.* 1998; **20** (2): 216-231.
- Blüher M, Kratzsch J, Paschke R et al. Plasma Levels of Tumor Necrosis Factor- α , Angiotensin II, Growth Hormone, and IGF-I Are Not Elevated in Insulin-Resistant Obese Individuals With Impaired Glucose Tolerance. *Diabetes Care* 2001; **24**: 328-334.
- Blüher M, Paschke R. Bedeutung des viszeralen Fettgewebes für das Metabolische Syndrom. *Deut. Med. Wochenschr.* 2003; **128**: 2319-2323.
- Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. *Diabetes* 1997; **46**: 3-10.
- Boden G, Lebed B, Schatz M et al. Effects of Acute Changes of Plasma Free Fatty Acids on Intramyocellular Fat Content and Insulin Resistance in Healthy Subjects. *Diabetes* 2001; **50**: 1612-1617.
- Boden G. Effects of Free Fatty Acids (FFA) on Glucose Metabolism: Significance for Insulin Resistance and Type 2 Diabetes. *Exp. Clin. Endocr. Diab.* 2003; **111**: 121-124.

- Bonora E, Kiechl S, Willeit J et al. Prevalence of Insulin Resistance in Metabolic Disorders. The Bruneck Study. *Diabetes* 1998; **47**: 1643-1649.
- Bouchard C. The causes of obesity: advances in molecular biology but stagnation on the genetic front. *Diabetologia* 1996; **39**: 1532-1533.
- Braissant O, Fougère F, Scotto C et al. Differential Expression of Peroxisome Proliferator-Activated Receptors (PPARs): Tissue Distribution of PPAR- α , - β , and - γ in the Adult Rat. *Endocrinology* 1996; **137**: 354-366.
- Brockman JA, Gupta RA, DuBois RN et al. Activation of PPAR γ Leads to Inhibition of Anchorage-Independent Growth of Human Colorectal Cancer Cells. *Gastroenterology* 1998; **115**: 1049-1055.
- Cederholm J, Wibell L. Insulin release and peripheral sensitivity at the oral glucose tolerance test. *Diabetes Res. Clin. Pr.* 1990; **10**: 167-175.
- Chao L, Marcus-Samuels B, Mason MM et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. *J. Clin. Invest.* 2000; **106**: 1221-1228.
- Chinetti G, Griglio S, Antonucci M et al. Activation of Proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. *J. Biol. Chem.* 1998; **273**: 25573-25580.
- Clausen JO, Hansen T, Bjoerbaek C et al. Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. *Lancet* 1995; **346**: 397-402.
- Coccozza S, Porcellini A, Riccardi G et al. NIDDM associated with mutation in tyrosine kinase domain of insulin receptor gene. *Diabetes* 1992; **41**: 521-526.
- Cole SA, Mitchell BD, Hsueh WC et al. The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. *Int. J. Obes. Relat. Metab. Disord.* 2000; **24** (4): 522-524.
- Conway JM, Irwin ML, Ainsworth BE et al. Estimating energy expenditure from the Minnesota Leisure Time Physical Activity and Tecumseh Occupational Activity questionnaires - a doubly labeled water validation. *J. Clin. Epidemiol.* 2002; **55**: 392-399.
- Davidson MB. Clinical Implications of Insulin Resistance Syndrome. *Am. J. Med.* 1995; **99**: 420-426.
- Davy KP, Hall JE. Obesity and hypertension: two epidemics or one? *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2004; **286** (5): 803-813.
- Day C. Thiazolidinediones: a new class of antidiabetic drugs. *Diabetic Med.* 1999; **16**: 179-192.
- DDG: Praxisleitlinien der Deutschen Diabetes-Gesellschaft. *Diabetes und Stoffwechsel* 2002; **11**: Suppl. 2.
- Deeb SS, Fajas L, Nemoto M et al. A Pro12Ala substitution in PPAR γ 2 associated with decreased receptor activity, lower body mass index, and improved insulin sensitivity. *Nat. Gen.* 1998; **20**: 284-287.
- DeFronzo RA, Tobin JD, Andres R et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am. J. Physiol.-Gastr. L.* 1979; **237**: G 214-G 223.
- DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. *Neth. J. Med.* 1997; **50**: 191-197.

- Delerive P, Gervois P, Fruchart JC et al. Induction of I κ B α Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor- α Activators. *J. Biol. Chem.* 2000; **275**: 36703-36707.
- Desvergne B, Wahli W. Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism. *Endocr. Rev.* 1999; **20** (5): 649-688.
- Devchand PR, Keller H, Peters JM et al. The PPAR α -leukotriene B4 pathway to inflammation control. *Nature* 1996; **384**: 39-43.
- Durnin JVGA, Womersley J. Body Fat assessed from Total-Body Density and its Estimation from Skinfold Thickness - Measurements on 481 Men and Women aged from 16 to 72 years. *Brit. J. Nutr.* 1974; **32** (1): 77-97.
- Epstein M. Diabetes and hypertension: the bad companions. *J. Hypertens.* 1997; **15** (2): 55-62.
- Eckel RH, Grundy SM, Zimmet PZ et al. The metabolic syndrome. *Lancet* 2005; **365**: 1415-1428.
- Ek J, Urhammer SA, Sørensen TIA et al. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor- γ 2 (PPAR- γ 2): divergent modulating effects on body mass index in obese and lean Caucasian men. *Diabetologia* 1999; **42**: 892-895.
- Ek J, Andersen G, Urhammer SA et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor- γ 2 (PPAR- γ 2) gene in relation to insulin sensitivity among glucose tolerant Caucasians. *Diabetologia* 2001; **44**: 1170-1176.
- Fernández-Real JM, Broch M, Vendrell J et al. Interleukin-6 Gene Polymorphism and Insulin Sensitivity. *Diabetes* 2000; **49**: 517-520.
- Ferrannini E, Haffner SM, Mitchell BD et al. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. *Diabetologia* 1991; **34** (6): 416-422.
- Ferrannini E. Insulin Resistance versus Insulin Deficiency in Non-Insulin-Dependent Diabetes Mellitus: Problems and Prospects. *Endocr. Rev.* 1998; **19** (4): 477-490.
- Fogelholm M, Kukkonen-Harjula K. Does physical activity prevent weight gain - a systematic review. *Obes. Rev.* 2000; **1** (2): 95-111.
- Ford ES, Giles WH, Dietz WH. Prevalence of the Metabolic Syndrome Among US Adults. Findings From the Third National Health and Nutrition Examination Survey. *JAMA - J. Am. Med. Assoc.* 2002; **287**: 356-359.
- Forman BM, Tontonoz P, Chen J et al. 15-Deoxy- $\Delta^{12,14}$ -prostaglandin J₂ is a ligand for adipocyte determination factor PPAR γ . *Cell* 1995; **83**: 803-812.
- Fox IH, John D, DeBruyne S et al. Hyperuricemia and hypertriglyceridemia: Metabolic basis for the association. *Metabolism*. 1985; **34**: 741-746.
- Frederiksen L, Brødbæk K, Fenger M et al. Studies of the Pro12Ala Polymorphism of the PPAR- γ Gene in the Danish MONICA Cohort: Homozygosity of the Ala Allele Confers a Decreased Risk of the Insulin Resistance Syndrome. *J. Clin. Endocr. Metab.* 2002; **87** (8): 3989-3992.
- Friedewald WT, Fredrickson DS, Levy RI et al. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. *Clin. Chem.* 1972; **18** (6): 499-502.

- Fritsche A, Madaus A, Tschritter O et al. Der Polymorphismus Pro12Ala im Peroxisomenproliferator-Aktivierten Rezeptor γ 2 (PPAR γ 2): Betazell-Funktion und Insulinsensitivität. *Deut. Med. Wochenschr.* 2001; **126**: 580-584.
- Gavrilova O, Marcus-Samuels B, Graham D et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. *J. Clin. Invest.* 2000; **105**: 271-278.
- Ghossaini M, Meyre D, Lobbens S. Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. *BMC Medical Genetics* 2005; **6**(11): www.biomedcentral.com/1471-2350/6/11.
- Goldberg GR, Black AE, Jebb SA et al. Critical evaluation of energy intake data using fundamental principles of energy physiology. 1. Derivation of cut-off limits to identify under-recording. *Eur. J. Clin. Nutr.* 1991; **45**: 569-581.
- Gründler S. Einfluss von Ernährungsfaktoren und körperlicher Aktivität auf die Insulinresistenz. Diplomarbeit Fachbereich Ernährungswissenschaften, Universität Jena 2004.
- Gurnell M, Savage DB, Chatterjee VK et al. The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor γ and Its Therapeutic Modulation. *J. Clin. Endocr. Metab.* 2003; **88** (6): 2412-2421.
- Haffner SM, Valdez RA, Hazuda HP et al. Prospective Analyses of the Insulin-Resistance Syndrome (Syndrome X). *Diabetes* 1992; **41** (6): 715-722.
- Haffner SM. Insulin sensitivity in subjects with type 2 diabetes. *Diabetes Care* 1999; **22**: 562-568.
- Haffner SM, Williams K, Rozek MM et al. Homeostasis Model Assessment. Insulin Resistance In Relation To 8-Years Of Incidence Of Cardiovascular Diseases. *Diabetologia* 2000; **43** (Suppl. 1): 1080.
- Hamann A, Münzberg H, Buttron P et al. Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects. *Eur. J. Endocrinol.* 1999; **141**: 90-92.
- Hamann A, Tafel J. Gen-Gen-Interaktionen bei der Regulation des Körpergewichts. *Aktuel. Ernährungsmed.* 2003; **28**: 137-142.
- Hanefeld M, Leonhard W. Das metabolische Syndrom. *Deut. Gesundheitswes.* 1981; **36**: 545-551.
- Hara K, Okada T, Tobe K et al. The Pro12Ala Polymorphism in PPAR γ 2 May Confer Resistance to Type 2 Diabetes. *Biochem. Bioph. Res. Co.* 2000; **271**: 212-216.
- Häring HU. Pathogenesis of type 2 diabetes: are there common causes for insulin resistance and secretion failure? *Exp. Clin. Endocr. Diab.* 1999; **107** (Suppl. 2): 17-23.
- Hart LM, Stolk RP, Heine RJ et al. Association of the insulin-receptor variant Met-985 with hyperglycemia and non-insulin-dependent diabetes mellitus in the Netherlands: a population-based study. *Am. J. Hum. Genet.* 1996; **59**: 1119-1125.
- Hasstedt SJ, Ren QF, Teng K et al. Effect of the Peroxisome Proliferator-Activated Receptor- γ 2 Pro¹²Ala Variant on Obesity, Glucose Homeostasis, and Blood Pressure in Members of Familial Type 2 Diabetic Kindreds. *J. Clin. Endocr. Metab.* 2001; **86**: 536-541.
- Hauner H. Übergewicht und Metabolisches Syndrom. In: *Diabetologie kompakt* (Hrsg. Helmut Schatz), Blackwell Wissenschafts-Verlag Berlin Wien, 2001: 114-120.

- HDS: The Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension of newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. *J. Hypertens.* 1993; **11**: 309-317.
- Himsworth HP, Kerr RB. Insulin sensitive and insulin-insensitive types of diabetes mellitus. *Clin. Sci.* 1939; **4**: 119.
- Hoffmann I, Kohl M, Groeneveld M et al. Development and validation of a new instrument to measure food intake. *Am. J. Clin. Nutr.* 1994; **59** (1): 284.
- Hokanson JE, Austin MA. Plasma triglyceride level is an independent risk factor for cardiovascular disease: a meta-analysis of population-based prospective studies. *J. Cardiovasc. Risk* 1996; **3**: 213-219.
- Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. *Diabetes* 1994; **43**: 1271-1278.
- Howard B, Howard W. Dyslipidemia in non-insulin-dependent diabetes mellitus. *Endocr. Rev.* 1994; **15**: 263-274.
- IDF: Diabetes Atlas, zweite Ausgabe, International Diabetes Federation 2003: www.idf.org.
- Irwin ML, Ainsworth BE, Conway JM et al. Estimation of Energy Expenditure from Physical Activity Measures: Determinants of Accuracy. *Obes. Res.* 2001; **9** (9): 517-525.
- Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001; **24**: 683-689.
- Issemann I, Green S. Activation of a number of the steroid receptor superfamily by peroxisome. *Nature* 1990; **347**: 645-650.
- Janka HU. Epidemiologie des Diabetes mellitus - Häufigkeit, Lebenserwartung, Todesursachen. In: *Diabetologie kompakt* (Hrsg. Helmut Schatz), Blackwell Wissenschafts-Verlag Berlin Wien, 2001: 1-5.
- Jones JR, Barrick C, Kim KA et al. Deletion of PPAR γ in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. *PNAS-Proc. Natl. Acad. Sci. USA* 2005; **102** (17): 6207-6212.
- Kadowaki T, Hara K, Yamauchi T et al. Molecular Mechanism of Insulin Resistance and Obesity. *Exp. Biol. Med.* 2003; **228** (10): 1111-1117.
- Kahara T, Takamura T, Hayakawa T et al. PPAR γ Gene Polymorphism Is Associated With Exercise-Mediated Changes of Insulin Resistance in Healthy Men. *Metabolis.* 2003; **52** (2): 209-212.
- Kahn CR, Vicent D, Doria A. Genetics of non-insulin-dependent (type II) diabetes mellitus. *Annu. Rev. Med.* 1996; **47**: 509-531.
- Kaplan NM. The deadly quartet - upper-body obesity, glucose-intolerance, hypertriglyceridemia, and hypertension. *Arch. Intern. Med.* 1989; **149** (7): 1514-1520.
- Kaplan NM. Management of Hypertensive Patients With Multiple Cardiovascular Risk Factors. *Am. J. Hypertens.* 2001; **14**: 221-224.
- Katz A, Nambi SS, Mather K et al. Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans. *J. Clin. Endocr. Metab.* 2000; **85**: 2402-2410.

- Kellerer M, Hennige A, Häring HU. Pathogenese des Typ-2-Diabetes. In: *Diabetologie kompakt* (Hrsg. Helmut Schatz), Blackwell Wissenschafts-Verlag Berlin Wien, 2001: 105-113.
- Kersten S. Peroxisome proliferator activated receptors and obesity. *Eur. J. Pharmacol.* 2002; **440**: 223-234.
- Klein BE, Klein R, Moss SE et al. Parental history of diabetes in a population- based study. *Diabetes Care* 1996; **19**: 827-830.
- Kliewer SA, Lenhard JM, Willson TM et al. A Prostaglandin J₂ metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. *Cell* 1995; **83**: 813-819.
- Koeffler HP. Peroxisome Proliferator-activated Receptor γ and Cancer. *Clin. Cancer Res.* 2003; **9**: 1-9.
- Kopelman PG. Obesity as a medical problem. *Nature* 2000; **404**: 635-643.
- Krey G, Braissant O, L'Horsset F et al. Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coaktivator-Dependent Receptor Ligand Assay. *Mol. Endocrinol.* 1997; **11** (6): 779-791.
- Krolewski AS, Canessa M, Warram JH et al. Predisposition to hypertension and susceptibility to renal disease to insulin-dependent diabetes mellitus. *New Engl. J. Med.* 1988; **318**: 140-145.
- Kubota N, Terauchi Y, Miki H et al. PPAR γ Mediates High-Fat Diet-Induced Adipocyte Hypertrophy and Insulin Resistance. *Mol. Cell* 1999; **4**: 597-609.
- Kylin E. Studien über das Hypertonie - Hyperglykämie - Hyperurikämie-syndrom. *Zentralb. Inn. Med.* 1923; **44**: 105-127.
- Laakso M, Malkki M, Kekäläinen P et al. Insulin Receptor Substrate-1 Variants in Non-Insulin-dependent Diabetes. *J. Clin. Invest.* 1994; **94**: 1141-1146.
- Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. *Atherosclerosis* 1998; **137**: 65-73.
- Lefebvre AM, Chen I, Desreumaux P et al. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APC^{Min}/mice. *Nat. med.* 1998; **4**: 1043-1057.
- Lehmann JM, Moore LB, Smith-Oliver TA et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). *J. Biol. Chem.* 1995; **270**: 12953-12956.
- Lehmann JM, Lenhard JM, Beverly BO et al. Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs. *J. Biol. Chem.* 1997; **272**: 3406-3410.
- Li AC, Brown KK, Silvestre MJ et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. *J. Clin. invest.* 2000; **106**: 523-531.
- Li WD, Lee JH, Price RA et al. The peroxisome proliferator-activated receptor gamma 2 Pro12Ala mutation is associated with early onset extreme obesity and reduced fasting glucose. *Mol. Genet. Metab.* 2000; **70**: 159-161.
- Li S, Chen W, Srinivasan SR et al. The Peroxisome Proliferator-Activated Receptor- γ 2 Gene Polymorphism (Pro12Ala) Beneficially Influences Insulin Resistance and Its Tracking From Childhood to Adulthood. The Bogalusa Heart Study. *Diabetes* 2003; **52**: 1265-1269.

-
- Liebl A, Neiß A, Spannheimer A et al. Kosten des Typ-2-Diabetes in Deutschland. Ergebnisse der CODE-2®-Studie. *Deut. Med. Wochenschr.* 2001; **126**: 585-589.
 - Lindi VI, Uusitupa MIJ, Lindström J et al. Association of the Pro12Ala Polymorphism in the PPAR- γ 2 Gene With 3-Year Incidence of Type 2 Diabetes and Body Weight Change in the Finnish Diabetes Prevention Study. *Diabetes* 2002; **51**: 2581-2586.
 - Livingstone MBE, Black AE. Markers of the Validity of Reported Energy Intake. *J. Nutr.* 2003; **133**: 895-920.
 - Luan J, Browne PO, Harding AH et al. Evidence for Gene-Nutrient Interaction at the PPAR γ Locus. *Diabetes* 2001; **50**: 686-689.
 - Machann J, Häring H, Schick F et al. Intramyocellular lipids and insulin resistance. *Diabetes Obes. Metab.* 2004; **6**: 239-248.
 - Malecki MT, Frey J, Klupa T et al. The Pro12Ala polymorphism of PPAR γ 2 gene and susceptibility to type 2 diabetes mellitus in a Polish population. *Diabetes Res. Clin. Pr.* 2003; **62**: 105-111.
 - Mangelsdorf DJ, Evans RM. The RXR Heterodimers and Orphan Receptors. *Cell* 1995; **83**: 841-850.
 - Masud S, Ye S. Effect of the peroxisome proliferator activated receptor- γ gene Pro12Ala variant on body mass index: a meta-analysis. *J. Med. Genet.* 2003; **40**: 773-780.
 - Matsuda M, DeFronzo RA. Insulin Sensitivity Indices obtained from oral Glucose Tolerance Testing. *Diabetes Care* 1999; **22**: 1462-1470.
 - Matthaei S, Stumvoll M, Kellerer M. Pathophysiology and Pharmacological Treatment of Insulin Resistance. *Endocr. Rev.* 2000; **21** 585-618.
 - Matthaei S, Stumvoll M, Häring HU. Thiazolidindione (Insulinsensitizer). Neue Aspekte in der Therapie des Diabetes mellitus Typ 2. *Deut. Ärztebl.* 2001; **98** (Heft 14): 912-918.
 - Matthews DR, Kosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985; **28**: 412-419.
 - Maxam AM, Gilbert W. Sequencing end-labeled DNA with base-specific chemical cleavages. *Method. Enzymol.* 1980; **65**: 499-560.
 - McAuley K, Williams SM, Mann JL et al. Diagnosing Insulin Resistance in the General Population. *Diabetes Care* 2001; **24** (3): 460-464.
 - Meigs JB, Wilson PWF, Nathan DM et al. Prevalence and Characteristics of the Metabolic Syndrome in the San Antonio Heart and Framingham Offspring Studies. *Diabetes* 2003; **52**: 2160- 2167.
 - Memisoglu A, Hu FB, Hankinson SE et al. Interaction between a peroxisome proliferator-activated receptor γ gene polymorphism and dietary fat intake in relation to body mass. *Hum. Mol. Genet.* 2003; **12** (22): 2923-2929.
 - Memisoglu A, Hu FB, Hankinson SE et al. Prospective Study of the Association Between the Proline to Alanine Codon 12 polymorphism in the PPAR γ Gene and Type 2 Diabetes. *Diabetes Care* 2003; **26**: 2915-2917.
 - Milne AC, McNeill G, Zakary A et al. Weight change as an indicator of energy imbalance during 7 day weighed food intake studies. *Ecol. Food Nutr.* 1991; **26**: 281-289.

- Minamikawa J, Tanaka S, Yamauchi M et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. *J. Clin. Endocr. Metab.* 1998; **83**: 1818-1820.
- Modan M, Halkin H, Karasik A et al. Elevated serum uric acid - a facet of hyperinsulinemia. *Diabetologia* 1987; **30**: 713-718.
- Mohamed-Ali V, Goodrick S, Rawesh A et al. Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor- α , in vivo. *J. Clin. Endocr. Metab.* 1997; **82** (12): 4196-4200.
- Möhlig M, Spranger J, Pfeiffer AFH. Adipozytokine. Bindeglied zwischen Übergewicht und Metabolischem Syndrom? *Med. Welt* 2005; **56**: 173-177.
- Moller DE, Kaufman KD. Metabolic syndrome: A Clinical and Molecular Perspective. *Annu. Rev. Med.* 2005; **56**: 45-62.
- Moore KJ, Rosen ED, Fitzgerald ML et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. *Nat. Med.* 2001; **7**: 41-47.
- Mori Y, Kim-Motoyama H, Katakura T et al. Effect of the Pro12Ala Variant of the Human Peroxisome Proliferator-Activated Receptor γ 2 Gene on Adiposity, Fat Distribution, and Insulin Sensitivity in Japanese Men. *Biochem. Biophys. Res. Co.* 1998; **251**: 195-198.
- Mueller E, Smith M, Sarraf P et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. *PNAS-Proc. Natl. Acad. Sci. USA* 2000; **97**: 10990-10995.
- Mullis KB, Faloona F, Scharf SJ et al. Specific enzymatic amplification of DNA in vitro: The polymerase chain reaction. *Cold Spring Harb. Sym.* 1986; **51**: 263-273.
- Nabel EG, Selwyn AP, Ganz P. Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. *J. Am. Coll. Cardiol.* 1990; **16**(2): 349-356.
- Nagy L, Tontonoz P, Alvarez JGA. Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPAR γ . *Cell* 1998; **93**: 229-240.
- National Institutes of Health. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), *JAMA-J. Am. Med. Assoc.* 2001; **285**: 2486-2897.
- Nicklas BJ, Van Rossum EFC, Berman DM et al. Genetic Variation in the Peroxisome Proliferator-Activated Receptor- γ 2 Gene (Pro12Ala) Affects Metabolic Responses to Weight Loss and Subsequent Weight Regain. *Diabetes* 2001; **50**: 2172-2176.
- Nielsen SJ, Popkin BM. Patterns and trends in food portion sizes, 1977-1998, *JAMA-J. Am. Med. Assoc.* 2003; **289**: 450-453.
- Nieters A, Becker N, Linseisen J et al. Polymorphisms in candidate obesity genes and their interaction with dietary intake of n-6 polyunsaturated fatty acids affect obesity risk in a sub-sample of the EPIC-Heidelberg cohort. *Eur. J. Nutr.* 2002; **41**: 210-221.
- Ofei F, Hurel S, Newkirk J et al. Effects of an engineered human anti-TNF- α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. *Diabetes* 1996; **45** (7): 881-885.

- O'Rahilly S, Choi WH, Patel P et al. Detection of mutations in insulin-receptor gene in NIDDM patients by analysis of single-stranded conformation polymorphisms. *Diabetes* 1991; **40**: 777-782.
- O'Riordan E, Chen J, Brodsky SV et al. Endothelial cell dysfunction: The syndrome in making. *Kidney Int.* 2005; **67**: 1654-1658.
- Pate RR, Pratt M, Blair SN et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports medicine. *JAMA-J. Am. Med. Assoc.* 1995; **273**: 402-407.
- Perseghin G, Caumo A, Caloni M et al. Incorporation of the Fasting Plasma FFA Concentration into QUICKI Improves Its Association with Insulin Sensitivity in Nonobese Individuals. *J. Clin. Endocr. Metab.* 2001; **86** (10): 4776-4781.
- Peters JM, Hennuyers N, Staels B et al. Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α -deficient Mice. *J. Biol. Chem.* 1997; **272**: 27307-27312.
- Pfeiffer AFH, Spranger J, Möhlig M. Adipositas. *Ärztliche Praxis* 2004; Zertifizierte Fortbildung: www.aerztlichepraxis.de.
- Pihlajamäki J, Miettinen R, Valve R et al. The Pro12Ala substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia. *Atherosclerosis* 2000; **151**: 567-574.
- Pinkney JH, Stehouwer CDA, Coppack SW et al. Endothelial dysfunction: Cause of the insulin resistance syndrome. *Diabetes* 1997; **46** (Suppl. 2): 9-13.
- Poirier O, Nicaud V, Cambien F et al. The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene is not associated with postprandial responses to glucose or fat tolerance tests in young healthy subjects: the European Atherosclerosis Research Study II. *J. Mol. Med.* 2000; **78**: 346-351.
- Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? *Eur. Heart J.* 2002; **23**: 831-834.
- Previs SF, Brunengraber H. Methods for measuring gluconeogenesis in vivo. *Curr. Opin. Clin. Nutr.* 1998; **1**: 461-465.
- Reaven GM. Banting lecture 1988. Role of Insulin Resistance in Human Disease. *Diabetes* 1988; **37**: 1595-1607.
- Ringel J, Engeli S, Distler A et al. Pro12Ala Missense Mutation of the Peroxisome Proliferator Activated Receptor γ 2 and Diabetes Mellitus. *Biochem. Biophys. Res. Co.* 1999; **254**: 450-453.
- Robitaille J, Després JP, Pérusse L et al. The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Québec Family Study. *Clin. Genet.* 2003; **63**: 109-116.
- Roden M, Petersen KF, Shulman GI et al. Nuclear Magnetic Resonance Studies of Hepatic Glucose Metabolism in Humans. *Recent. Prog. Horm. Res.* 2001; **56**: 219-237.
- Rosen ED, Walkey CJ, Puigserver P et al. Transcriptional regulation of adipogenesis. *Gene. Dev.* 2000; **14**: 1293-1307.

- Rosmond R, Chagnon M, Bouchard C et al. The Pro12Ala PPAR γ 2 gene missense mutation is associated with obesity and insulin resistance in Swedish middle-aged men. *Diabetes Metab. Res.* 2003; **19**: 159-163.
- Saez E, Tontonoz P, Nelson MC et al. Activators of the nuclear receptor PPAR γ enhance colon polyp formation. *Nat. Med.* 1998; **4**: 1058-1061.
- Saez E, Olson P, Ewans RM et al. Genetic deficiency in PPAR γ does not alter development of experimental prostate cancer. *Nat. Med.* 2003; Advance Online Publication: www.nature.com/naturemedicine.
- Saltiel AR, Kahn R. Insulin signalling and the regulation of glucose and lipid metabolism. *Nature* 2001; **414**: 799-806.
- Sanger F, Nicklen S, Coulson AR et al. DNA sequencing with chain terminating inhibitors. *PNAS-Proc. Natl. Acad. Sci. USA* 1977; **74** (12): 5463-5467.
- Sarraf P, Mueller E, Smith WM et al. Loss-of-Function Mutations in PPAR γ Associated with Human Colon Cancer. *Mol. Cell* 1999; **3**: 799-804.
- Schmidt I. Metabolic Diseases: the Environment Determines the Odds, Even for Genes. *News Physiol. Sci.* 2002; **17**: 115-121.
- Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. *J. Lipid Res.* 1996; **37** (5): 907-925.
- Schulze MB, Kroke A., Bergmann MM et al. Differences of blood pressure estimates between consecutive measurements on one occasions: Implications for inter-study comparability of epidemiologic studies. *Eur. J. Epidemiol.* 2000; **16**: 891-898.
- Schutz Y, Weinsier RL, Hunter GR et al. Assessment of Free-Living Physical Activity in Humans: An Overview of Currently Available and Proposed New Measures. *Obes. Res.* 2001; **9** (6): 368-379.
- Shulman GI. Cellular mechanisms of insulin resistance. *J. Clin. Invest.* 2000; **106**: 171-176.
- Siri WE. Body composition from fluid spaces and density: Analysis of Methods. Reprinted from: *Techniques for Measuring Body Composition*, 1961: 223-244, Herausgeber Brozek J, Henschel A, Washington. *Nutrition* 1993; **9** (5): 481-491.
- Snyder EE, Walts B, Pérusse L et al. The Human Obesity Gene Map: The 2003 Update. *Obes. Res.* 2004; **12** (3): 369-439.
- Spiegelman BM, Flier JS. Adipogenesis and Obesity: Rounding Out the Big Picture. *Cell* 1996; **87**: 377-389.
- Spranger J, Kroke A, Möhlig M et al. Adiponectin and protection against type 2 diabetes mellitus. *Lancet* 2003; **361**: 226-228.
- Spranger J, Möhlig M, Pfeiffer AFH. Das Metabolische Syndrom: Bedeutung von Zytokinen als endokrine und metabolische Signalmoleküle. *Aktuel. Ernährungsmed.* 2003; **28**: 143-150.
- Stears AJ, Byrne CD. Adipocyte metabolism and the metabolic syndrome. *Diabetes Obes. Metab.* 2001; **3**: 129-142.
- Steinberg D. Oxidative Modification of LDL and Atherogenesis. *Circulation* 1997; **5**: 1062-1071.

- Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. *Diabetologia* 2002; **45** (5): 623-634.
- Steppan CM, Bailey ST, Bhat S et al. The hormon resistin links obesity to diabetes. *Nature* 2001; **409** (6818): 307-312.
- Stern C. The Hardy-Weinberg law. *Science* 1943; **97**: 137-138.
- Stern MP, Haffner SM. Body Fat Distribution and Hyperinsulinemia as Risk Factors for Diabetes and Cardiovascular Disease. *Arteriosclerosis* 1986; **6**: 123-130.
- Stumvoll M, Mitrakou A, Pimenta W et al. Use of the Oral Glucose Tolerance Test to Assess Insulin Release and Insulin Sensitivity. *Diabetes Care* 2000; **23**: 295-301.
- Stumvoll M, Van Haeften T, Fritsche A et al. Oral Glucose Tolerance Test Indexes for Insulin Sensitivity and Secretion Based on Various Availabilities of Sampling Times. *Diabetes Care* 2001; **24** (4): 796-797.
- Stumvoll M, Häring H. Resistin and Adiponectin - of Mice and Men. *Obes. Res.* 2002; **10** (11): 1197-1199.
- Swarbrick MM, Chapman CML, McQuillan BM et al. A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor- γ 2 is associated with combined hyperlipidaemia in obesity. *Eur. J. Endocrinol.* 2001; **144**: 277-282.
- Tai ES, Corella D, Deurenberg-Yap M et al. Differential effects of the C1431T and Pro12Ala PPAR γ gene variants on plasma lipids and diabetes risk in an Asian population. *J. Lipid Res.* 2004; **45**: 674-685.
- Taylor SI. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. *Diabetes* 1992; **41**: 1473-1490.
- Taylor AA. Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus. *Endocrin. Metab. Clin.* 2001; **30** (4): 983-997.
- Tontonoz P, Hu E, Spiegelman BM et al. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. *Curr. Opin. Genet. Dev.* 1995; **5** (5): 571-576.
- Tontonoz P, Singer S, Forman BM et al. Terminal differentiation of human liposarcoma cells induced by ligands for the peroxisome proliferator-activated receptor γ and the retinoid X receptor. *PNAS-Proc. Natl. Acad. Sci. USA* 1997; **94**: 237-241.
- Tontonoz P, Nagy L, Alvarez JG et al. PPAR γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. *Cell* 1998; **93**: 241-252.
- Tooke J. The association between insulin resistance and endotheliopathy. *Diabetes Obes. Metab.* 1999; **1** (Suppl. 1): 17-22.
- Uppenberg J, Svensson C, Jaki M et al. Crystal structure of the ligand binding domain of the human nuclear receptor PPAR γ . *J. Biol. Chem.* 1998; **273**: 31108-31112.
- Vaccaro O, Mancini FP, Ruffa G et al. Fasting plasma free fatty acid concentrations and Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) γ 2 gene in healthy individuals. *Clin. Endocrinol.* 2002; **57**: 481-486.
- Vague J. La différenciation sexuelle, facteur déterminant des formes de l'obésité. *Presse Med.* 1947; **30**: 339-340.

- Valve R, Sivenius K, Miettinen R et al. Two Polymorphisms in the Peroxisome Proliferator-Activated Receptor- γ Gene Are Associated with Severe Overweight among Obese Women. *J. Clin. Endocr. Metab.* 1999; **84**: 3708-3712.
- Vamecq J, Latruffe N: Medical significance of peroxisome proliferator-activated receptors. *Lancet* 1999; **354**: 141-148.
- Vogelstein B, Gillespie D. Preparative and analytical purification of DNA from agarose. *PNAS-Proc. Natl. Acad. Sci. USA* 1979; **76**: 615-619.
- Vozarova B, Weyer C, Hanson K et al. Circulating Interleukin-6 in Relation to Adiposity, Insulin Action, and Insulin Secretion. *Obes. Res.* 2001; **9**: 414-417.
- Walczak R, Tontonoz P. PPARadigms an PPARadoxes: expanding roles for PPAR γ in the control of lipid metabolism. *J. Lipid Res.* 2002; **43**: 177-186.
- Wareham NJ, Jakes RW, Rennie KL et al. Validity and repeatability of the EPIC-Norfolk Physical Activity Questionnaire. *Int. J. Epidemiol.* 2002; **31**: 168-174.
- Warram JH, Martin BC, Krolewski AS et al. Slow glucose removal rate and hyperinsulinemia precede the development of type 2 diabetes in the offspring of diabetic patients. *Ann. Intern. Med.* 1990; **113** (12): 909-915.
- Weiss EP, Kulaputana O, Ghiu IA et al. Endurance training-induced changes in insulin response to oral glucose are associated with the peroxisome proliferator-activated receptor- γ 2 Pro12Ala genotype in men but not in women. *Metabolism.* 2005; **54** (1): 97-102.
- Werman A, Hollenberg A, Solanes G et al. Ligand-independent activation domain in the N-terminus of peroxisome proliferator-activated receptor γ (PPAR γ). *J. Biol. Chem.* 1997; **272**: 20230-20235.
- Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia. *J. Clin. Endocr. Metab.* 2001; **86**:1930-1935.
- WHO: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. *Report of WHO Consultation* 1999: www.WHO.int.
- WHO: Obesity: preventing and managing the global epidemic. Report of a WHO consultation. *WHO Technical Report; Geneva 2000*: Series No. 894.
- WHO/ FAO Expert Consultation: Diet, Nutrition and the Prevention of Chronic Diseases: *Report of a Joint WHO/ FAO Expert Consultation, Geneva 28 January-1 February 2002*; World Health Organization 2003.
- Wood N, Johnson RB, Streckfus CF et al. Comparison of body composition and periodontal disease using nutritional assessment techniques: Third National Health and Nutrition Examination Survey (NHANES III). *J. Clin. Periodontol.* 2003; **30**: 321-327.
- Yamauchi T, Kamon J, Waki H et al. The Mechanisms by Which Both Heterozygote Peroxisome Proliferator-activated Receptor γ (PPAR γ) Deficiency and PPAR γ Agonists Improve Insulin Resistance. *J. Biol. Chem.* 2001; **276**: 41245-41254.
- Yamauchi T, Waki H, Kamon J et al. Inhibition of RXR and PPAR γ ameliorates diet-induced obesity and type 2 diabetes. *J. Clin. Invest.* 2001; **108**: 1001-1013.
- Yang WS, Lee WJ, Funahashi T et al. Weight Reduction Increases Levels of an Adipose-Derived Anti-Inflammatory Protein, Adiponectin. *J. Clin. Endocr. Metab.* 2001; **86**: 3815-3819.

- Yen CJ, Beamer BA, Negri C et al. Molecular Scanning of the Human Peroxisome Proliferator Activated Receptor γ (hPPAR γ) Gene in Diabetic Caucasiens: Identification of a Pro12Ala PPAR γ 2 Missense Mutation. *Biochem. Bioph. Res. Co.* 1997; **241**: 270-274.
- Zhang Y, Proenca R, Maffei M et al. Positional cloning of the mouse obese gene and its human homologue. *Nature* 1994; **372**: 425-432.
- Zhang Y, Kumar S, Barnett AH et al. Intrinsic Site-Specific Differences in the Expression of Leptin in Human Adipocytes and Its Autocrine Effects on Glucose Uptake. *J. Clin. Endocr. Metab.* 1999; **84** (7): 2550-2556.
- Zimmet P, Hodge A, Nicolson M et al. Serum leptin concentration, obesity, and insulin resistance in Western Samoans: cross sectional study. *Brit. Med. J.* 1996; **313**: 965-969.
- Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. *Nature* 2001; **414** (6865): 782-787.

